International Stem Cell (ISCO) Net Income towards Common Stockholders (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Net Income towards Common Stockholders of -$203000.0 for Q4 2025, down 1791.67% year-over-year from $12000.0 in Q4 2024, and down 800.0% quarter-over-quarter from $29000.0 in Q3 2025.
International Stem Cell (ISCO) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Net Income towards Common Stockholders for 16 consecutive years, with -$203000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders fell 1791.67% year-over-year to -$203000.0; the TTM figure through Dec 2025 stood at -$1.6 million (down 394.92% YoY), while the FY2025 annual figure was -$7.9 million, down 3.76% from the prior year.
- Net Income towards Common Stockholders retreated to -$203000.0 in Q4 2025 per ISCO's latest filing, from $29000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $259000.0 in Q2 2023 and bottomed at -$937000.0 in Q3 2021.
- Historically, Net Income towards Common Stockholders has averaged -$264550.0 across 5 years, with a median of -$167000.0 in 2023.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders jumped 13050.0% — and 2025, when it plunged 1791.67%.
- International Stem Cell's Net Income towards Common Stockholders stood at -$354000.0 in 2021, then surged by 145.2% to $160000.0 in 2022, then plunged by 303.12% to -$325000.0 in 2023, then jumped by 103.69% to $12000.0 in 2024, then slumped by 1791.67% to -$203000.0 in 2025.
- Business Quant data shows ISCO's Net Income towards Common Stockholders at -$203000.0 in Q4 2025, $29000.0 in Q3 2025, and -$450000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | -69,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -71,000.00 |
| Dec 31, 2025 | -203,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | -450,000.00 |
| Mar 31, 2025 | -935,000.00 |
| Dec 31, 2024 | 12,000.00 |
| Sep 30, 2024 | -125,000.00 |
| Jun 30, 2024 | 62,000.00 |
| Mar 31, 2024 | -264,000.00 |
| Dec 31, 2023 | -325,000.00 |
| Sep 30, 2023 | -131,000.00 |
| Jun 30, 2023 | 259,000.00 |
| Mar 31, 2023 | -34,000.00 |
| Dec 31, 2022 | 160,000.00 |
| Sep 30, 2022 | -343,000.00 |
| Jun 30, 2022 | -2,000.00 |
| Mar 31, 2022 | -9,000.00 |
| Dec 31, 2021 | -354,000.00 |
| Sep 30, 2021 | -937,000.00 |
| Jun 30, 2021 | -901,000.00 |